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Abstract
Objectives—To compare treatment outcomes by starting CD4 counts using data from the
CIPRA-South Africa trial.
Design—Observational cohort study.
Methods—Patients presenting to primary care clinics with CD4 cell counts <350 cells/mm3 were
randomized to either doctor- or nurse-managed HIV care and followed for at least two years after
ART initiation. Clinical and laboratory outcomes were compared by baseline CD4 count.
Results—812 patients were followed for a median of 27.5 months and 36% initiated with a CD4
count >200. While 10% of patients failed virologically (VF), the risk was nearly double among
those with a CD4 ≤200 vs. >200 (12.2% vs. 6.8%). 21 deaths occurred, with a five-fold increased
risk for the low CD4 group (3.7% vs. 0.7%). After adjustment, those with a CD4 count ≤200 had
twice the risk of death/VF (HR 1.9; 95% CI: 1.1–3.3) and twice the risk of incident tuberculosis
(HR: 1.90; 95% CI: 0.89–4.04) as those >200. Those with either a CD4 ≤200 (HR 2.1; 1.2–3.8) or
a WHO IV condition (HR 2.9; 0.93–8.8) alone had a two to three-fold increased risk of death/VF
vs. those with neither, but those with both conditions had a 4-fold increased risk (HR 3.9; 95% CI:
1.9–8.1). We observed some increased loss to follow-up among those initiating <200 (HR 0.79;
95% CI: 0.50–1.25).
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Conclusions—Patients initiating ART with higher CD4 counts had reduced mortality,
tuberculosis and less virologic failure than those initiated at lower CD4 counts. Our data support
increasing CD4 count eligibility criteria for ART initiation.
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INTRODUCTION
With the increase in global funding for HIV/AIDS, the developing world has seen
unprecedented access to lifesaving antiretroviral therapy (ART) over the past five years.
Funds mandated towards rapidly scaling up access to ART have been successfully targeted
and nearly four million people are now on ART[1]. When large-scale treatment programs
began, in most cases, treatment was limited to patients with advanced disease. The ideal
time to initiate ART is currently unknown[2]. While guidelines for resource rich
environments currently recommend initiating at CD4 counts < 350[3;4], developing country
guidelines recommended initiating ART at CD4 counts ≤200 in the absence of clinical
disease until November 2009 when the WHO recommended initiating treatment at CD4 <
350 [5;6]. As new evidence from resource rich environments has accumulated showing that
starting ART at higher CD4 counts is associated with better treatment outcomes[7–9],
programs in resource limited settings, given limited resources, must make difficult choices
about whether or not to raise initiating CD4 count thresholds to higher levels.
The debate about when to initiate treatment is difficult as ART is a lifelong treatment that
has significant cost and can have significant side effects. On an individual level decisions
about when to initiate therapy must balance the potential medical benefits of initiating at
higher CD4 counts[10] and reductions in HIV transmission[11] with the risk of toxicity and
the costs associated with longer time on treatment. On a public health level, a decision about
when to initiate ART must balance any expected population level benefits of initiating
treatment at higher CD4 counts with the cost implications of potentially increased demand
for treatment if treatment thresholds are raised, but also any possible cost savings associated
with earlier treatment including reduced hospitalization and treatment of opportunistic
infections.[12] The first step towards rationalizing decisions on when to initiate ART is to
assess, using data from resource limited settings, the likely treatment benefits that can be
expected.
Recent evidence from the developed world suggest starting at CD4 counts below 350
improves treatment outcomes and decreases mortality compared to waiting to below
200[13–17], and the benefits may even begin when initiating at CD4 counts above 350,[13]
yet limited evidence from the developing world exists to inform policy[18]. To date only
one study from a developing country has attempted to randomize patients to initiate ART at
CD4 counts below 350 compared to waiting until the CD4 count drops below 200. An
interim analysis of the Comprehensive International Program of Research on AIDS
(CIPRA)-Haiti trial[19;20] found that initiating at CD4 counts under 200 was associated
with a 4-fold increased risk of mortality and a 2-fold increased risk of incident tuberculosis
compared to starting at a CD4 count between 200–350.
The recent changes in WHO guidelines have yet to be adopted globally[21]. In order to
support decision making around when to initiate ART, we assessed the association between
treatment outcomes and starting ART at higher CD4 counts using data collected as part of
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the CIPRA-SA randomized trial comparing nurse monitored antiretroviral treatment with
doctor monitored treatment in South Africa[22].
METHODS
Study Design
The data for this study was collected as part of the CIPRA-SA trial, an unblinded,
prospective, randomized controlled trial comparing nurse- vs. doctor-monitored HIV care
and demonstrated equivalence of the two monitoring strategies for treatment failure over
two years (HR 1.09; 95%CI 0.89–1.33)[22]. The study enrolled 812 HIV-positive ART
naïve patients ≥16 years old with a CD4 count ≤350 or prior AIDS defining illness (CDC
category B/C) at one of two sites in South Africa (Soweto, Johannesburg and
Masiphumelele, Cape Town). All patients were managed under South African National
Guidelines for HIV treatment and were given standard ART regimens consisting of
lamivudine given with either zidovudine or stavudine and either efavirenz or nevirapine[5].
A protease inhibitor (PI) based regimen was used in a limited number of cases (N=62) for
women of childbearing potential with a CD4 count >350. Patients were randomized 1:1 to
have their HIV care monitored by either a nurse or a clinical officer and were followed for a
minimum of 96 weeks. Details of the CIPRA-SA trial can be found elsewhere.[22]
Patient Follow-up and Data Collection
Patients were seen at baseline and then returned for follow up visits at weeks 0, 2, 4, 9, 12,
then every 12 weeks. At each visit patients had a clinical examination, symptom screening
for tuberculosis and a blood draw for lab testing including CD4 count, viral load,
hematology and biochemistry.
While current guidelines in South Africa allow for initiation of ART for patients with CD4
counts ≤200 or WHO Stage IV condition[5], and because the CIPRA-SA study enrolled
patients with a CD4 count ≤350, we conducted a prospective cohort study assessing
differences in treatment failure among those initiated at a CD4 count >200 and those
initiated ≤200.
Definition of Study Variables
The primary exposure was CD4 cell count >200 vs. ≤200 at ART initiation. CD4 count was
measured at randomization in the main CIPRA-SA study and was assessed using CD4+ flow
cytometry (FlowCount Fluorospheres, Beckman Coulter-Immunotech, France).
We assessed the impact of starting treatment at higher CD4 counts on three indicators of
program failure: 1) treatment failure (an indicator of death or failure to achieve or maintain
viral suppression); 2) incident tuberculosis; and 3) program failures (indicated by patients
who leave care). Virologic failure was defined as either: 1) failure to reach a 1.5 log10 drop
in viral load by 12 weeks on treatment; or 2) two consecutive viral loads >1,000 copies/ml
within one month of each other after 24 weeks on treatment. We defined loss to follow up
(LTFU) as missing three or more consecutive study visits (in the main study shown as lost to
follow up and defaulting clinic schedule); we did not include patients who voluntarily
withdrew from the study as many of these subjects would remain in care just not on the
study protocol.
To determine if there were any association between toxicity related outcomes and initiating
treatment at higher CD4 counts, we examined the relation between initiating CD4 count and
treatment related toxicities. Details of the toxicities that occurred are given elsewhere[22]
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but included any toxicity which required discontinuation of the study regimen, with a
resulting treatment interruption of >6 weeks.
For all analyses, person-time accrued from initiation of treatment through the date of the
earliest of: 1) experiencing a treatment outcome (defined above); 2) completion of 48
months of treatment; 3) becoming lost to follow-up (except in analyses where LTFU was the
outcome); or 4) date of closing the dataset (January 20, 2009).
All patients in the CIPRA-SA trial signed informed consent forms. The CIPRA-SA trial was
approved by the Institutional Review Boards (IRB) of the University of the Witwatersrand
and the University of Cape Town. The Boston University IRB gave approval for analysis of
the data in a de-identified manner.
Statistical Methods
We compared differences between study groups by stratifying our data by baseline CD4
count group. We looked for crude associations between baseline predictors and treatment
outcomes and compared groups using relative risks and 95% confidence intervals. We
explored the relation between initiating CD4 count and treatment failure by describing the
rate of treatment failure using crude Kaplan-Meier curves. We fit adjusted models of the
association between low initiating CD4 count on treatment failure using Cox Proportional
Hazards regression. All models were adjusted for age, sex (stratified at baseline into males,
pregnant women and non-pregnant women), study site and randomization group. We did not
include post-baseline measures as these may be caused by baseline CD4 count. We looked
for a dose response between higher CD4 count and treatment outcomes by fitting a model
with finer categorizations of baseline CD4 count. Finally we looked for interactions between
CD4 count and other markers of immunosuppression at baseline (e.g. viral load, WHO
stage, body mass index (BMI)).
RESULTS
Cohort Description
Baseline characteristics of the 812 subjects enrolled in the CIPRA-SA cohort stratified by
baseline CD4 count group are shown in Table 1. Patients were followed for a median of 27.5
months (IQR 13.8–33.1) with no differences by study group. As expected based on
randomization, roughly half of those in each CD4 count group had nurse-monitored and half
had doctor-monitored ART care. Median age was 32 years and more than 2/3 were female
with no differences by CD4 count group. Prior ART use (typically for prevention of mother-
to-child transmission), was balanced between CD4 groups. Those in the low CD4 group
were more likely to have nevirapine in their baseline regimen than efavirenz while those in
the higher CD4 count group were more likely to have lopinavir-ritonavir.
518 subjects (64%) fell into the low CD4 count group (≤200) while the remaining 294
(36%) were in the high CD4 count group (>200). Those in the low CD4 group were more
immunosuppressed at baseline as indicated by viral loads ≥100,000 (RR: 1.67; 95%CI: 1.43
– 1.95), WHO stage IV (RR: 2.32; 95% CI: 1.62–3.33) or CDC C (RR: 1.42; 95% CI: 1.16–
1.73). Few subjects had extremely low or high CD4 counts; only 16% (85/518) of those in
the low CD4 group had a CD4 count <50 and only 16% (46/294) of those in the high CD4
count group had a CD4 count >350.
Death and Virologic Failure
Treatment outcomes by CD4 group are shown in Table 2. There were 21 deaths in the study
(2.6%); however in crude analyses, those with a baseline CD4 count ≤200 had a five-fold
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increased risk vs. those >200 (RR: 5.4; 95% CI: 1.3–23.0). Virologic failure occurred in
10% of the cohort, with the majority (84%) of these virologic failures based on 2
consecutive viral loads >1000 and not based on failure to achieve a 1.5 log10 drop in viral
load from baseline by 12 weeks (16% 13/83). Those with a CD4 ≤200 at baseline had nearly
twice the crude risk of virologic failure as those >200 (RR: 1.79; 95% CI: 1.10–2.90). The
Kaplan-Meier curve of death or virologic failure presented in Figure 1a shows that the
difference between the two groups in death and virologic failure emerges mainly between 6
and 24 months on treatment.
Table 3 shows three different crude and adjusted models of the relation between baseline
CD4 count and virologic failure or death. We present three separate models which are
identical except that they use different categorizations of CD4 count (models 1 and 2) or
include an interaction between baseline WHO stage and CD4 count (model 3). Model 1,
which uses the CD4 categories used previously (≤200 vs. >200) shows that after adjusting
for age, sex and pregnancy, site, treatment arm and other indicators of immunosuppression,
those with a baseline CD4 count ≤200 had twice the risk of virologic failure or death (HR:
1.94; 95% CI: 1.14–3.30). Having a baseline WHO stage IV (HR: 1.98; 95% CI: 1.18–3.33),
a viral load >100,000 vs. <10,000 (HR: 2.05; 95% CI: 0.71–5.89) and having a nelfinavir-
based regimen (HR: 4.27; 95% CI: 1.17–15.6) were also predictive of virologic failure or
death independent of CD4 count.
In model 2 we looked for a CD4 count dose response between decreasing baseline CD4
count and risk of death or virologic failure by stratifying baseline CD4 count into finer
categories (0–99, 100–199, 200–299, ≥300). After adjustment we found those with a CD4
count between 100–199 and those with a CD4 count <100 had a roughly 3-fold increased
risk of death or virologic failure as those ≥300 (CD4 <100 vs. >300, HR 3.08; 95% CI:
0.92–10.4 and CD4 100–199 vs. >300, HR: 3.23; 95% CI: 0.99–10.6) while those with a
CD4 200–299 had twice the risk (HR: 2.00; 95% CI: 1.19–3.37). Thus higher baseline CD4
count does appear to be associated with lower risk of virologic failure and death.
We also looked for interactions between baseline CD4 count group and other markers of
immunosuppression. Model 3 shows the results of the only significant interaction we
identified, that between baseline CD4 count (≤200 vs. >200) and baseline WHO Stage IV.
Compared to the reference group of those with a baseline CD4 count >200 and no WHO
Stage IV condition, those with either a WHO Stage IV condition alone or a CD4 count ≤200
alone had a 2 to 3-fold increased risk of death or virologic failure (HR: 2.87; 95% CI: 0.93–
8.83 and HR: 2.14; 95% CI: 1.20–3.81 respectively). However, those with both a WHO
Stage IV condition and a CD4 count ≤200 at baseline had a 4-fold increased risk of death or
virologic failure vs. those with neither condition (HR: 3.91; 95% CI: 1.88–8.14).
Tuberculosis
Overall about 6% of all subjects in the study developed incident tuberculosis over the course
of follow up with substantially more of it occurring among those initiated on ART at CD4
counts ≤200 than among those initiated >200 (8.0% vs. 3.1%, RR 2.6; 95% CI: 1.3–5.3)
(Table 2). In a Kaplan-Meier analysis (Figure 1c) we note that the majority of the difference
between the two groups emerged within the first 24 months on treatment. In table 4, we
present two separate models of incident TB which are identical except that they use different
categorizations of CD4 count (models 1 uses ≤200 vs. > 200 while Model 2 uses <50, 50–
199, ≥ 200). After adjusting for site, treatment group, age, sex, use of a PI based regimen,
baseline viral load, WHO stage, and BMI (data not shown) using proportional hazards
regression we found that those initiated on ART at CD4 counts ≤200 cells/ul were twice as
likely to develop TB compared to those initiated >200 cells/ul (HR: 1.9; 95% CI: 0.89–4.0)
(Table 4, model 1). When we further stratified the lowest CD4 count group into those above
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and below 50 (model 2) we found that those with a CD4 count <50 vs. >200 were at
strongly increased risk of incident TB (HR 3.4; 95% CI: 1.4–8.5) while those 50–200 vs.
>200 were at lower increased risk (HR 1.60; 95% CI: 0.73–3.5) (Table 4).
Loss to Follow Up
Nearly 12% of the cohort were lost to follow-up and LTFU was more common among those
with a baseline CD4 count >200 than ≤ 200 (14.3% vs. 10.2%)(Table 2). After adjusting for
age, sex, baseline WHO stage, viral load, use of a PI, treatment arm and site, we found a
small decreased risk of being LTFU among those initiated on ART with lower CD4 counts
(≤200) vs. those initiated at higher CD4 counts (>200) (HR: 0.79; 95% CI 0.50–1.25).
Figure 1b shows that the difference between the groups emerges only after 24 months, the
minimum potential follow-up time for the cohort. Those with a baseline WHO stage IV
condition had an increased risk of LTFU (HR 1.61; 0.93–2.79), as did those with (data not
shown).
Toxicities
Toxicity endpoints were experienced by about 17% of the entire cohort (Table 2). We
observed small differences in rates of toxicities between CD4 count groups slightly favoring
those with baseline CD4 counts ≤200 vs. >200 (15.6% vs. 18.0%) (Figure 1d). After
adjusting for age, sex, baseline WHO stage, viral load, treatment regimen, treatment arm and
site, females (HR: 1.95; 95% CI: 1.17–3.24), those who with a BMI >30 vs. 18.5–30 (HR
2.17; 95% CI: 1.41–3.34) or a baseline WHO stage IV condition (HR 1.91; 1.15–3.18) were
at increased risk of toxicity failure, but we found little differences between CD4 count
groups (HR 0.78; 95% CI: 0.53–1.16) (data not shown). Use of lopinavir-ritonavir vs.
efavirenz based regimens decreased the risk of toxicity (HR: 0.40; 95% CI: 0.16–1.02).
Nevirapine use was associated with increased risk of toxicity vs. efavirenz based regimens
in unadjusted analyses (HR: 1.46; 95% CI: 0.99–2.16), but the association disappeared after
adjustment (HR: 1.01; 95% CI: 0.63–1.61).
DISCUSSION
The results of analyses of the CIPRA-SA trial data show a clearly increased risk of death or
virologic failure associated with initiating ART at lower CD4 counts. We found that those
who started ART at CD4 counts ≤200 had roughly twice the risk of death or virologic
failure as those initiated at CD4 counts >200 (HR: 1.94; 95% CI: 1.14–3.30) and twice the
risk of developing incident tuberculosis (HR:1.90; 95% CI 0.89–4.04). These findings are in
line with numerous observational studies from resource-limited settings showing low
baseline CD4 count is a major predictor of death and loss to follow-up[23–27]. Recently an
interim analysis of the CIPRA-HT001 trial in Haiti showed a nearly four-fold increased risk
of death among those started with a CD4 count ≤200 vs. 200–350,[19] very similar to our
five-fold increased risk (RR: 5.4; 95% CI: 1.3–23.0)[19]. Thus a body of evidence is
beginning to emerge showing the benefits of earlier treatment initiation in resource-limited
settings. This, along with a recent analysis by Lawn and colleagues[28] showing that the
longer a patient maintains a CD4 count <100, the higher the risk of death suggest that
starting patients at higher CD4 counts may allow them to maintain their CD4 count above
the point at which they are at increased risk of death.
Our findings are also consistent with data from resource rich environments. Observational
data has shown that higher CD4 counts are associated with lower risk of death[7;9]. More
recently, Kitahata and colleagues have shown[13] that patients initiating ART at CD4 counts
>500 had substantially reduced risk of mortality vs. those below. While our data cannot be
used to comment on CD4 counts >350, our finding of decreased mortality and virologic
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failure risk associated with having a starting CD4 count >300 is suggestive of a dose-
response with increasing baseline CD4 count associated with better outcomes.
While we found a substantial benefit to earlier ART initiation, we also found a slightly
increased risk of being lost to follow-up among those with higher baseline CD4 counts
which could potentially offset some of the benefits of initiating treatment earlier. However,
we urge caution in interpreting these results. Under ideal conditions, assessing the
effectiveness of initiating ART at higher CD4 counts would come from randomizing
patients to either: 1) immediate initiation of ART when the CD4 count falls <350; and 2)
follow patients and delay ART until the CD4 count falls <200[14;29]. In both arms patients
would be followed from the time of their first CD4 count <350. In our study patients were
initiated onto ART at enrollment as long as their CD4 count was <350 so we do not have
any follow-up time to approximate what happens to patients in the time their CD4 count is
between 200–350; however, we anticipate some death and loss to follow-up occurs in this
time. While methods exist to adjust for this lead time bias,[30] they require pre-ART data
which we did not have.
The current analysis has several strengths. The data were from a large prospective
randomized trial with excellent follow-up data at standardized intervals which allowed the
assessment of the impact of starting treatment at higher CD4 counts. Although the data was
from a randomized trial of another intervention, because the trial showed no differences
between randomization groups (i.e. nurse- vs. doctor-monitored care) and because
adjustment for randomization group had no impact on our current results, there is little
evidence that the primary intervention had any impact on our findings.
Still the current analysis should be considered in light of several limitations. First, as noted
above, we did not have the ideal comparison group to assess death and virologic failure (i.e.
a group followed from a CD4 count of 350 until 200 and then initiated on ART). Thus, any
deaths occurring between 350-200 would not be included in our analysis. Since we are
missing deaths in the high CD4 count group, this analysis likely underestimates the
treatment benefits of starting at higher CD4 counts. Thus our estimates cannot be considered
the true causal effect of starting treatment at higher CD4 counts. Second, as the data came
from a randomized trial with conservative definitions of toxicity, many subjects who were
treatment failures for toxicity might have otherwise continued on treatment under usual
practice conditions. This could have biased our toxicity results towards the null and
prevented us from observing a true difference between the groups if one existed. Third, in
our analysis of loss to follow-up, we were not able to determine the final outcomes of
patients lost and therefore we cannot say if patients left care because they were feeling well
nor could we determine how many of them have since died. Finally, as the data were from a
trial, the study population may have been healthier than the general clinic population.
In conclusion, we found that patients initiated on standard first-line South African ART
regimens were at increased risk of death and virologic failure if initiated at CD4 counts <200
compared to those initiated >200. This is consistent with findings from developed areas
which have shown that the benefits of starting at earlier CD4 counts outweigh the risks of
toxicity and long-term adherence. While the cost implications are unknown, national and
international guidelines on the topic of when to initiate ART should consider our findings
when deciding on whether to increase initiating CD4 count thresholds. If thresholds are
increased, substantial efforts will need to be made to move patients into care earlier in their
disease progression in order to obtain the maximum benefit from ART.
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Kaplan-Meier analysis of time to a) death or virologic failure, b) tuberculosis c) loss to
follow-up and d) toxicity by baseline CD4 count group among 812 patients enrolled in the
CIPRA-SA trial at two sites in South Africa*
* CIPRA-SA = Comprehensive International Program of Research on AIDS-South Africa,
TB = tuberculosis. Note that y-axis goes from 0 to 0.5.
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Table 1
Differences in baseline characteristics by baseline CD4 count group among 812 patients enrolled in the
CIPRA-SA trial at two sites in South Africa*
Variable
Baseline CD4 ≤ 200
(N=518)




Follow-up (months) (Median (IQR)) 27.5 (13.4–33.1) 27.5 (13.8–33)
Site Johannesburg 299 (57.7%) 150 (51.0%) Reference
Cape Town 219 (42.3%) 144 (49.0%) 0.86 (0.74 – 1.01)
Study group Primary Health
Care Nurse
260 (50.2%) 144 (49.0%) Reference
Medical Officer 258 (49.8%) 150 (51.0%) 0.98 (0.85 – 1.12)
Gender Male 155 (29.9%) 84 (28.6%) Reference
Female 363 (70.1%) 210 (71.4%) 0.98 (0.90 – 1.08)
Age at baseline (Median (IQR) 32 (28.1–37.3) 32.5 (27.8–36.7)
Race Black/African 515 (99.4%) 289 (98.3%) Reference
Mixed Race 3 (0.6%) 5 (1.7%) 0.34 (0.080 – 1.41)
Baseline ART*
regimen
d4T-3TC-EFV 370 (71.4%) 227 (77.2%) Reference
d4T-3TC-NVP 119 (23.0%) 34 (11.6%) 1.87 (1.32 – 2.65)
d4T-3TC-LPVr 25 (4.8%) 30 (10.2%) 0.54 (0.33 – 0.90)
d4T-3TC-NLF 4 (0.8%) 3 (1.0%) 0.82 (0.19 – 3.63)
Prior ART
exposure*
None 390 (75.3%) 219 (74.5%) Reference
sdNVP 113 (21.8%) 54 (18.4%) 1.14 (0.85 – 1.52)
AZT mono 2 (0.4%) 4 (1.4%) 0.28 (0.05 – 1.54)
NVP/AZT 13 (2.5%) 16 (5.4%) 0.47 (0.23 – 0.97)
ART 0 (0%) 1 (0.3%)
WHO stage
at baseline
1 71 (13.8%) 80 (28.0%) Reference
2 154 (29.8%) 96 (33.6%) 1.25 (1.07 – 1.47)
3 197 (38.2%) 84 (29.4%) 1.44 (1.22 – 1.69)
4 94 (18.2%) 26 (9.1%) 2.32 (1.62 – 3.33)
CDC category A 177 (34.2%) 124 (42.2%) Reference
B 135 (26.1%) 94 (32.0%) 1.00 (0.82 – 1.22)
C 206 (39.8%) 76 (25.9%) 1.42 (1.16 – 1.73)
CD4 count at baseline (Median (IQR)) 123 (77–159) 254.5 (224–308)
Baseline hemoglobin (Median (IQR)) 11.7 (10.3–13.1) 12.4 (11.4–13.5)
BMI at baseline (Median (IQR)) 23.1 (20.5–26.6) 24.1 (21.3–28.4)
Baseline viral
load
<100,000 174 (33.6%) 177 (60.2%) Reference
≥ 100,000 344 (66.4%) 117 (39.8%) 1.67 (1.43 – 1.95)
Viral load at baseline (× 1000) Median
(IQR)
201.5 (64.8–525) 66.9 (20.9–188)
*
CI = confidence interval, CIPRA-SA = Comprehensive International Program of Research on AIDS-South Africa, ART = antiretroviral therapy,
sdNVP = Single done Nevirapine, AZT = Zidovudine, NVP = Nevirapine, d4T = Stavudine, 3TC = Lamivudine, EFV = Efavirenz, NLF =
Nelfinavir, LPVr = Lopinavir-ritonavir
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Table 2
Reasons for ART treatment failure stratified by baseline CD4 count group among 812 patients enrolled in the
CIPRA-SA trial at two sites in South Africa*










Death 19/518 (3.7%) 2/294 (0.7%) 21 (2.6%) 5.39 (1.26 – 22.0)
Virologic Failure 63/518 (12.2%) 20/294 (6.8%) 83 (10.2%) 1.79 (1.10 – 2.90)
  1.5 log drop# 8/518 (1.5%) 5/294 (1.7%) 13 (1.6%) 0.91 (0.30 – 2.75)
  2 VL > 1000^ 55/518 (10.6%) 15/294 (5.1%) 70 (8.6%) 2.08 (1.20 – 3.62)
Incident tuberculosis 41/515 (8.0%) 9/293 (3.1%) 50 (6.2%) 2.59 (1.28 – 5.26)
OTHER STUDY OUTCOMES
Toxicity failure 81/518 (15.6%) 53/294 (18.0%) 134 (16.5%) 0.87 (0.63 – 1.19)
Loss to follow-up 52/518 (10.0%) 42/294 (14.3%) 94 (11.6%) 0.70 (0.48 – 1.03)
  Default clinic schedule 40/518 (7.7%) 30/294 (10.2%) 70 (8.6%) 0.76 (0.48 – 1.19)
  Lost to follow-up 12/518 (2.3%) 12/294 (4.1%) 24 (3%) 0.57 (0.26 – 1.25)
*
CI = confidence interval, CIPRA-SA = Comprehensive International Program of Research on AIDS-South Africa
#
Failure to achieve a 1.5 log10 drop in viral load from baseline at 12 weeks on treatment
^
VL = viral load, 2 consecutive viral loads > 1,000 copies/ml within one month of each other after 24 weeks on treatment
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Table 4
Crude and adjusted hazard ratios (HR) of incident tuberculosis among 812 patients enrolled in the CIPRA-SA
trial at two sites in South Africa*
Model 1 Model 2









Age at baseline (continuous) 1.02 (0.98–1.06) 1.02 (0.98–1.06) 1.02 (0.98–1.06) 1.02 (0.98–1.06)
BMI at baseline (continuous) 0.90 (0.84–0.97) 0.91 (0.84–0.99) 0.90 (0.84–0.97) 0.91 (0.84–0.99)
Female 0.71 (0.40–1.26) 1.30 (0.66–2.55) 0.71 (0.40–1.26) 1.29 (0.65–2.54)
Johannesburg vs Cape Town 0.58 (0.33–1.02) 0.60 (0.32–1.12) 0.58 (0.33–1.02) 0.69 (0.36–1.32)
Nurse vs. Doctor 0.92 (0.53–1.60) 1.06 (0.59–1.89) 0.92 (0.53–1.60) 1.03 (0.58–1.84)
Regimen with a PI* 0.54 (0.13–2.22) 0.93 (0.21–4.04) 0.54 (0.13–2.22) 0.98 (0.22–4.27)
WHO Stage IV vs. III/II/I 2.09 (1.09–4.00) 1.27 (0.63–2.56) 2.09 (1.09–4.00) 1.12 (0.55–2.29)
Viral load >100,000 vs <10,000 2.37 (0.73–7.66) 1.23 (0.36–4.22) 2.37 (0.73–7.66) 1.18 (0.34–4.07)
Viral load 10,000 – 100,000 vs <10,000 0.65 (0.17–2.51) 0.53 (0.13–2.08) 0.65 (0.17–2.51) 0.50 (0.13–1.97)
CD4 ≤ 200 vs > 200 2.64 (1.28–5.43) 1.90 (0.89–4.04)
CD4 0–49 vs. ≥200 5.95 (2.57–13.8) 3.39 (1.35–8.51)
CD4 50–199 vs. ≥200 2.05 (0.96–4.36) 1.60 (0.73–3.51)
*
Crude models are adjusted for each predictor by itself while adjusted models are adjusted for all other variables in the model. CI = confidence
interval, HR = hazard ratio, PI = protease inhibitor, CIPRA-SA = Comprehensive International Program of Research on AIDS-South Africa. Crude
models are adjusted for each predictor by itself while adjusted models are adjusted for all other variables in the model. All adjusted models
included regimen, age, sex, site, randomization group, baseline viral load, WHO stage and BMI. Model 1 included a dichotomous predictor for
baseline CD4 count (≤ 200 vs > 200). Model 2 included three categories for baseline CD4 count 0–49, 150–199, ≥200).
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